Eye Diseases
Conditions
Interventions
intravitreal injection of aflibercipt
Sponsors
Egypt health insurance
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Any participant to be included in the study should have: normal or controlled blood pressure. normal Hba1c or controlled (maximum 6.5%). normal or controlled lipogram. Patients aged =18 years with center-involved macular edema due to CRVO (CMT =250 µm on OCT). Best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters)
Exclusion criteria
Exclusion criteria: Exclusion criteria comprised the following: pregnancy or lactation. glaucoma. cataract. previous vitreoretinal or filtration surgery. iris neovascularization. any systemic or ocular disorder in the study eye that may confound the interpretation of the study results. previous treatment with any anti-VEGF agents. systemic anti-angiogenic medications. intraocular corticosteroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity changes at follow up time points. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in central macular thickness and choroidal thickness as measured by OCT. Reporting any ocular or systemic complications related to intravitreal injection of Aflibercept. | — |
Countries
Egypt
Contacts
Public ContactGamal El Deen Rashed
Dr. Gamal El Deen Rashed. staff member ophthalmology department Asyut university
Outcome results
None listed